Articles tagged "Kidney/liver transplantation"

2019 American Transplant Congress
Iguratimod Inhibits the Donor Specific Antibodies Production and Attenuates the Antibody Mediated Rejection in Rat Kidney Transplantation
Z. Wang, M. Zheng, H. Chen, S. Li, Z. Han, J. Tao, X. Ju, R. Tan, M. Gu
No.300 Guangzhou Road of Nanjing, Nanjing, China
*Purpose: Our study was designed to investigate the efficacy and related mechanisms of Iguratimod (T-614) in the inhibition of DSAs following kidney transplantation.*Methods: A rat…
2019 American Transplant Congress
Outcomes for Liver Transplant Recipients on Renal Replacement Therapy: Who Cannot Wait for Safety Net
A. Pita¹, N. Kaur¹, M. Lo², A. F. Sabour¹, V. Tristan¹, Y. Genyk¹, M. K. Nadim³, L. Sher¹
¹Department of Surgery, Keck Medical Center of USC, Los Angeles, CA, ²Department of Preventive Medicine, Keck Medical Center of USC, Los Angeles, CA, ³Department of Medicine, Keck Medical Center of USC, Los Angeles, CA
*Purpose: The purpose of this study is to identify risk factors for poor outcomes for liver transplant (LT) recipients on renal replacement therapy (RRT) in…
2019 American Transplant Congress
Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression
J. A. Seaman¹, S. G. Westphal², F. Qiu³, D. Bremers⁴, D. Florescu⁵
¹College of Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Nephrology, University of Nebraska Medical Center, Omaha, NE, ³Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁴Donate Life, Nebraska Medicine, Omaha, NE, ⁵Internal Medicine Division of Infectious Disease, University of Nebraska Medical Center, Omaha, NE
*Purpose: The aim of our study was to compare the outcomes one-year after renal transplant with a focus on opportunistic infections in patients who received…
2019 American Transplant Congress
Wide Geographic Variability in the Proportion of Donors with Cardiac Death – Lost Opportunities for Organ Donation?
E. M. Sonnenberg¹, D. S. Goldberg², J. Y. Hsu³, P. P. Reese², P. L. Abt¹
¹Department of Surgery, University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA
*Purpose: Donation after cardiac death (DCD) donors are largely not considered by organ procurement organization (OPO) metrics, as DCD donors are only counted in donor…
2019 American Transplant Congress
Sequential Liver Kidney Transplant Has Comparable Outcomes As Combined Liver Kidney Transplant Except For Ckd 5 In Patient With Cld With Ckd In Live Donor Program- Retrospective Analysis Of 2182 Cases
S. Verma, S. Naganathan, S. Gupta
Center for Liver and Biliary Sciences, Max Superspeciality hospital, New Delhi, India
*Purpose: Chronic Kidney disease (CKD) is common in patient with Chronic liver disease (CLD). It is difficult to distinguish between CKD and Hepatorenal syndrome (HRS)…
2019 American Transplant Congress
Facilitators and Barriers to Implementing the Live Donor Champion Program
A. D. Love¹, D. R. Helfer¹, S. Rasmussen¹, M. Johnson¹, J. M. Konel¹, J. R. Wellen², S. M. Nazarian³, E. King¹, D. L. Segev¹, T. Hwee¹, A. M. Cameron¹, M. L. Henderson¹, E. J. Gordon⁴, J. M. Garonzik Wang¹
¹Surgery, Johns Hopkins University, Baltimore, MD, ²Abdominal Transplant Surgery, Washington University School of Medicine, St. Louis, MO, ³Surgery, Penn Transplant Institute, Philadelphia, PA, ⁴Surgery, Northwestern Feinberg School of Medicine, Chicago, IL
*Purpose: The Live Donor Champion (LDC) Program is an intervention designed to increase kidney transplant candidate knowledge about living donor kidney transplantation (LDKT) and ability…
2019 American Transplant Congress
A Clinical Pharmacogenetic Model to Predict the Efficacy of Sirolimus during the Early Administration in Renal Transplant Recipients
Z. Wang, S. Fei, Z. Han, J. Tao, R. Tan, M. Gu
No.300 Guangzhou Road of Nanjing, Nanjing, China
*Purpose: This study was to develop a clinical pharmacogenetic model to predict the efficacy of sirolimus during the early administration in renal transplant recipients. 70…
2019 American Transplant Congress
Combined Liver and Delayed Kidney Transplantation (CLKT) Enables Similar Patient Survival as Liver Transplantation Alone (LTA): Propensity Score-Based Comparison
B. Ekser¹, C. A. Kubal¹, R. S. Mangus¹, P. Mihaylov¹, J. A. Fridell¹, L. R. Timsina¹, M. Lacerda², M. Ghabril², J. A. Powelson¹, W. C. Goggins¹
¹Transplant Division - Department of Surgery - Indiana University, Indianapolis, IN, ²Gastroenterology, Indiana University, Indianapolis, IN
*Purpose: We previously showed the positive impact of delayed KT in CLKT on patient survival compared to simultaneous KT. It is well known from the…
2019 American Transplant Congress
Allograft Quality Impacts Simultaneous Liver Kidney Transplant Survival Outcomes in Recipients That Undergo Liver Re-Transplantation
J. Reyes, M. Eerhart, C. Blanton, P. Chlebeck, E. Polyak, Y. Yankol, L. Fernandez
Department of Surgery, University of Wisconsin - Madison, Madison, WI
*Purpose: The only effective therapeutic strategy for irreversible liver graft failure is re-transplantation. The impact of liver and kidney quality in secondary SLK (sSLK) survival…
2019 American Transplant Congress
The Clinical & Economic Impact Of Allosensitization In Liver Alone And Simultaneous Liver Kidney Transplantation
M. Askar¹, G. Saracino¹, A. Elsabbagh², J. Fung³, T. Srinivas⁴, S. Flechner⁵, J. Trotter¹, G. Testa¹, B. Kaplan⁶, G. Klintmalm¹, J. Schold⁵, S. Asrani¹
¹Transplant Center, Baylor Scott & White, Dallas, TX, ²St. Vincent Health, Indianapolis, IN, ³University of Chicago Medicine, Chigao, IL, ⁴Intermountain Healthcare, Salt Lake City, UT, ⁵Cleveland Clinic, Cleveland, OH, ⁶Transplant Center, Baylor Scott & White, Temple, TX
*Purpose: Allosensitization is thought to have marginal impact among patients that undergo liver transplantation (LTA); further among simultaneous liver kidney transplantation (SLKT), livers may protect…